SUR1 Antibody (S289-16)

Immunocytochemistry/ Immunofluorescence: SUR1 Antibody (S289-16) [NBP2-59320]

Immunocytochemistry/Immunofluorescence: SUR1 Antibody (S289-16) [NBP2-59320] - Analysis using Mouse Anti-SUR1 Monoclonal Antibody, Clone S289-16. Tissue: Neuroblastoma cell line SK-N-BE. Species: Human. Fixation: 4% Formaldehyde for 15 min at RT. Primary Antibody: Mouse Anti-SUR1 Monoclonal Antibody at 1:100 for 60 min at RT. Secondary Antibody: Goat Anti-Mouse ATTO 488 at 1:100 for 60 min at RT. Counterstain: Phalloidin Texas Red F-Actin stain; DAPI (blue) nuclear stain at 1:1000, 1:5000 for 60min RT, 5min RT. Localization: Cytoplasm, Nucleus. Magnification: 60X. (A) DAPI (blue) nuclear stain (B) Phalloidin Texas Red F-Actin stain (C) SUR1 Antibody (D) Composite.

Immunocytochemistry/ Immunofluorescence: SUR1 Antibody (S289-16) [NBP2-59320]

Immunocytochemistry/Immunofluorescence: SUR1 Antibody (S289-16) [NBP2-59320] - Glial fibrillary acidic protein (GFAP)-positive specimens from human contusion- traumatic brain injury (TBI) exhibit sulfonylurea receptor 1 (SUR1) expression in astrocytes.Double immunolabeling for SUR1 (red) and GFAP (green) showed astrocyte expression of SUR1; merged images confirm co-localization (yellow); in situ hybridization of the same tissue section for Abcc8 messenger RNA showed positive signal co-localized with GFAP-positive, SUR1-expressing astrocytes; arrowheads point to cells with all three signals. Image collected and cropped by CiteAb from the following publication (//www.liebertpub.com/doi/10.1089/neu.2018.5986) licensed under a CC-BY license.

Immunocytochemistry/ Immunofluorescence: SUR1 Antibody (S289-16) [NBP2-59320] -

Immunocytochemistry/ Immunofluorescence: SUR1 Antibody (S289-16) [NBP2-59320] - Glial fibrillary acidic protein (GFAP)–positive specimens from human contusion- traumatic brain injury (TBI) exhibit KIR6.2 expression in astrocytes. (A) Immunolabeling for KIR6.2 showed sparse immunoreactivity in the control specimen (CTR) vs. widespread expression in a GFAP-positive specimen from contusion-TBI. (B) Double immunolabeling for GFAP (red) & KIR6.2 (green) showed astrocyte expression of KIR6.2; merged images confirm co-localization (yellow); in situ hybridization of the same tissue section for Kcnj11 messenger RNA showed positive signal co-localized with GFAP-positive, KIR6.2-expressing astrocytes; arrowheads point to cells with all three signals. (C) Double immunolabeling showed that KIR6.2 (red) & sulfonylurea receptor 1 (SUR1; green) were co-localized (yellow) in astrocytes. (D) ImmunoFRET for SUR1 (magenta) & KIR6.2 (red) showed co-assembly of SUR1-KIR6.2 heteromers (yellow pseudocolor) in astrocytes. (E) Double immunolabeling showed that KIR6.2 (green) & transient receptor potential cation channel subfamily M member 4 (TRPM4) (red) were co-localized in astrocytes. The findings illustrated are representative of all GFAP-positive specimens from eight cases of human contusion-TBI. (case #2, 11 days post-TBI; case #5, 1 day post-TBI) Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/30160201), licensed under a CC-BY license. Not internally tested by Novus Biologicals.